Please login to the form below

Not currently logged in
Email:
Password:

Waldenstrom's macroglobulinaemia

This page shows the latest Waldenstrom's macroglobulinaemia news and features for those working in and with pharma, biotech and healthcare.

Janssen's Imbruvica fails to win NICE backing in lymphoma

Janssen's Imbruvica fails to win NICE backing in lymphoma

There was some positive news for Janssen, however, as Imbruvica received a positive recommendation to treat Waldenström's Macroglobulinaemia (WM) in adults who have had at least one prior therapy.

Latest news

  • NICE rejects Imbruvica for non-Hodgkin’s lymphoma NICE rejects Imbruvica for non-Hodgkin’s lymphoma

    Draft guidance cites insufficient cost-effectiveness evidence for J&J’s drug. NICE has once again rejected Johnson &Johnson's Imbruvica (ibrutinib) for use on the NHS in England and Wales, ... Imbruvica is used to treat Waldenstrom's macroglobulinaemia

  • FDA clears Imbruvica as chemo alternative for first-line CLL FDA clears Imbruvica as chemo alternative for first-line CLL

    mantle cell lymphoma (MCL) and the treatment of Waldenström's macroglobulinaemia. ... AbbVie and J&J's drug also achieved partial or complete responses in 82% of patients, compared to 35% of the chemotherapy group.

  • AZ takes majority stake in cancer drug developer Acerta AZ takes majority stake in cancer drug developer Acerta

    Acalabrutinib is a Bruton's tyrosine kinase (Btk) inhibitor in the same class as Janssen/Pharmacyclics/Abbvie's Imbruvica (ibrutinib) drug for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia, which ... This week it agreed a

  • AZ confirms interest in Acerta takeover AZ confirms interest in Acerta takeover

    as a treatment for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia. ... Analysts have speculated that AZ's interest in Acerta could draw other possible suitors out of the shadows.

  • Imbruvica filed as first-line leukaemia therapy Imbruvica filed as first-line leukaemia therapy

    of Waldenström's macroglobulinaemia. ... Imbruvica is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor - licensed by Janssen from Pharmacyclics in 2011 in a deal valued at up to $975m.

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
foxandcat.online

We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...